Brown Advisory’s Heron Therapeutics HRTX Stock Holding History

Brown Advisory’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-307,827	Closed	-$5.56M	–	1083
2016 Q2	$5.56M	Buy	307,827 +11,471	+4%	+$224K	0.02%	347
2016 Q1	$5.63M	Sell	296,356 -4,585	-2%	-$90.5K	0.02%	347
2015 Q4	$8.04M	Buy	300,941 +13,651	+5%	+$365K	0.03%	307
2015 Q3	$7.01M	Buy	+287,290	New	+$9.57M	0.03%	315

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Brown Advisory's HRTX Position: Q3 2016 in Review

Brown Advisory sold out of Heron Therapeutics (HRTX) in Q3 2016, closing a stake of 307,827 shares — an estimated $5.56M sold.

Brown Advisory first reported a position in HRTX in Q3 2015 and held it in 4 quarters. The position peaked at $8.04M in Q4 2015. 91 funds tracked by Wall St. Rank hold HRTX as of Q3 2016.

Brown Advisory reported no remaining Heron Therapeutics position as of Q3 2016 after selling out during the quarter.
Brown Advisory sold 307,827 Heron Therapeutics shares in Q3 2016, an estimated $5.56M.
Brown Advisory first reported a position in Heron Therapeutics in Q3 2015 and held it in 4 quarters.
Brown Advisory's Heron Therapeutics position peaked at $8.04M in Q4 2015.
91 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2016.

Based on Brown Advisory's 13F filing for Q3 2016, filed 14 Nov 2016.